Berglund, E. D., C. Y. Li, H. A. Bina, S. E. Lynes, M. D. Michael, A. B. Shanafelt, A. Kharitonenkov and D. H. Wasserman (2009). "Fibroblast growth factor 21 controls glycemia via regulation of hepatic glucose flux and insulin sensitivity." Endocrinology 150(9): 4084-4093.
Borroto-Escuela, D. O., A. O. Tarakanov and K. Fuxe (2016). "FGFR1-5-HT1A Heteroreceptor Complexes: Implications for Understanding and Treating Major Depression." Trends Neurosci 39(1): 5-15.
Carosi, J. M., C. Fourrier, J. Bensalem and T. J. Sargeant (2022). "The mTOR-lysosome axis at the centre of ageing." FEBS Open Bio 12(4): 739-757.
Decarie-Spain, L., S. Sharma, C. Hryhorczuk, V. Issa-Garcia, P. A. Barker, N. Arbour, T. Alquier and S. Fulton (2018). "Nucleus accumbens inflammation mediates anxiodepressive behavior and compulsive sucrose seeking elicited by saturated dietary fat." Mol Metab 10: 1-13.
Duarte, R. R. R., C. Troakes, M. Nolan, D. P. Srivastava, R. M. Murray and N. J. Bray (2016). "Genome-wide significant schizophrenia risk variation on chromosome 10q24 is associated with altered cis-regulation of BORCS7, AS3MT, and NT5C2 in the human brain." Am J Med Genet B Neuropsychiatr Genet 171(6): 806-814.
Elkin, S. R., A. M. Lakoduk and S. L. Schmid (2016). "Endocytic pathways and endosomal trafficking: a primer." Wien Med Wochenschr 166(7-8): 196-204.
Erickson, A. and R. Moreau (2016). "The regulation of FGF21 gene expression by metabolic factors and nutrients." Horm Mol Biol Clin Investig 30(1).
Esmaeili, M. H., B. Bahari and A. A. Salari (2018). "ATP-sensitive potassium-channel inhibitor glibenclamide attenuates HPA axis hyperactivity, depression- and anxiety-related symptoms in a rat model of Alzheimer's disease." Brain Res Bull 137: 265-276.
Flippo, K. H. and M. J. Potthoff (2021). "Metabolic Messengers: FGF21." Nat Metab 3(3): 309-317.
Hollenbeck, P. J. and J. A. Swanson (1990). "Radial extension of macrophage tubular lysosomes supported by kinesin." Nature 346(6287): 864-866.
Kewcharoenwong, C., S. A. Prabowo, G. J. Bancroft, H. A. Fletcher and G. Lertmemongkolchai (2018). "Glibenclamide Reduces Primary Human Monocyte Functions Against Tuberculosis Infection by Enhancing M2 Polarization." Front Immunol 9: 2109.
Kharitonenkov, A., T. L. Shiyanova, A. Koester, A. M. Ford, R. Micanovic, E. J. Galbreath, G. E. Sandusky, L. J. Hammond, J. S. Moyers, R. A. Owens, J. Gromada, J. T. Brozinick, E. D. Hawkins, V. J. Wroblewski, D. S. Li, F. Mehrbod, S. R. Jaskunas and A. B. Shanafelt (2005). "FGF-21 as a novel metabolic regulator." J Clin Invest 115(6): 1627-1635.
Kuo, Y. Y., H. Y. Tsai, Y. M. Kuo, S. F. Tzeng, P. S. Chen, P. H. Hsu, Y. T. Lin and P. C. Chen (2023). "Glibenclamide promotes FGF21 secretion in interscapular BAT and attenuates depression-like behaviors in male mice with HFD-induced obesity." Life Sci 328: 121900.
Lan, T., D. A. Morgan, K. Rahmouni, J. Sonoda, X. Fu, S. C. Burgess, W. L. Holland, S. A. Kliewer and D. J. Mangelsdorf (2017). "FGF19, FGF21, and an FGFR1/beta-Klotho-Activating Antibody Act on the Nervous System to Regulate Body Weight and Glycemia." Cell Metab 26(5): 709-718 e703.
Lu, Z. and S. Xu (2006). "ERK1/2 MAP kinases in cell survival and apoptosis." IUBMB Life 58(11): 621-631.
Martin, G. M., P. C. Chen, P. Devaraneni and S. L. Shyng (2013). "Pharmacological rescue of trafficking-impaired ATP-sensitive potassium channels." Front Physiol 4: 386.
Nestler, E. J. and W. A. Carlezon, Jr. (2006). "The mesolimbic dopamine reward circuit in depression." Biol Psychiatry 59(12): 1151-1159.
Pereira-Leal, J. B. and M. C. Seabra (2001). "Evolution of the Rab family of small GTP-binding proteins." J Mol Biol 313(4): 889-901.
Pu, J., C. M. Guardia, T. Keren-Kaplan and J. S. Bonifacino (2016). "Mechanisms and functions of lysosome positioning." J Cell Sci 129(23): 4329-4339.
Schneier, F. R., M. Slifstein, A. E. Whitton, D. A. Pizzagalli, J. Reinen, P. J. McGrath, D. V. Iosifescu and A. Abi-Dargham (2018). "Dopamine Release in Antidepressant-Naive Major Depressive Disorder: A Multimodal [(11)C]-(+)-PHNO Positron Emission Tomography and Functional Magnetic Resonance Imaging Study." Biol Psychiatry 84(8): 563-573.
Shukla, A., K. Kumar and A. Singh (2014). "Association between obesity and selected morbidities: a study of BRICS countries." PLoS One 9(4): e94433.
Sutton, C. A., A. M. L'Insalata and T. L. Fazzino (2022). "Reward sensitivity, eating behavior, and obesity-related outcomes: A systematic review." Physiol Behav 252: 113843.
Tsai, S. F., P. L. Hsu, Y. W. Chen, M. S. Hossain, P. C. Chen, S. F. Tzeng, P. S. Chen and Y. M. Kuo (2022). "High-fat diet induces depression-like phenotype via astrocyte-mediated hyperactivation of ventral hippocampal glutamatergic afferents to the nucleus accumbens." Mol Psychiatry 27(11): 4372-4384.
Tye, K. M., J. J. Mirzabekov, M. R. Warden, E. A. Ferenczi, H. C. Tsai, J. Finkelstein, S. Y. Kim, A. Adhikari, K. R. Thompson, A. S. Andalman, L. A. Gunaydin, I. B. Witten and K. Deisseroth (2013). "Dopamine neurons modulate neural encoding and expression of depression-related behaviour." Nature 493(7433): 537-541.
Wang, Q., J. Yuan, Z. Yu, L. Lin, Y. Jiang, Z. Cao, P. Zhuang, M. J. Whalen, B. Song, X. J. Wang, X. Li, E. H. Lo, Y. Xu and X. Wang (2018). "FGF21 Attenuates High-Fat Diet-Induced Cognitive Impairment via Metabolic Regulation and Anti-inflammation of Obese Mice." Mol Neurobiol 55(6): 4702-4717.
Wang, X., L. Zhu, J. Hu, R. Guo, S. Ye, F. Liu, D. Wang, Y. Zhao, A. Hu, X. Wang, K. Guo and L. Lin (2020). "FGF21 Attenuated LPS-Induced Depressive-Like Behavior via Inhibiting the Inflammatory Pathway." Front Pharmacol 11: 154.
Yang, C., C. Jin, X. Li, F. Wang, W. L. McKeehan and Y. Luo (2012). "Differential specificity of endocrine FGF19 and FGF21 to FGFR1 and FGFR4 in complex with KLB." PLoS One 7(3): e33870.
Yaqoob, U., K. Jagavelu, U. Shergill, T. de Assuncao, S. Cao and V. H. Shah (2014). "FGF21 promotes endothelial cell angiogenesis through a dynamin-2 and Rab5 dependent pathway." PLoS One 9(5): e98130.
Bittolo, T., C. A. Raminelli, C. Deiana, G. Baj, V. Vaghi, S. Ferrazzo, A. Bernareggi and E. Tongiorgi (2016). "Pharmacological treatment with mirtazapine rescues cortical atrophy and respiratory deficits in MeCP2 null mice." Scientific Reports 6(1): 19796.